Posts

Showing posts with the label CAR T-cell

Top Companies in CAR T-cell Therapy (2026)

Image
Last updated October 2026 · Originally published November 2022 At first, the trend was subtle. But, the tide has swelled and created a craze for promising CAR-T product candidates. Driven by approvals of the CAR-T products Kymriah and Yescarta, there has been a rush to chase the next CAR-T success. CAR T-cell therapy (Chimeric Antigen Receptor T-Cell) is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.” The global CAR t-cell therapy market size was valued at USD 5.8 billion in 2025 and is projected to grow from USD 6.9 billion in 2026 to USD 22.3 billion by 2033, at a CAGR of 18.1% from 2026 to 2033. The market in North America dominated with a revenue share of 61.1% in 2025. Market growth is driven by rising cancer prevalence, adoption of personalized c...

CAR-T reshaped cancer treatment. Can it change autoimmune disease, too?

Image
More than 15 years ago, Aimee Payne was searching for a way to hunt down — and target — the cells behind a potentially life-threatening condition that initially triggers painful blisters on the skin. The University of Pennsylvania dermatologist found an answer in another corner of the university that housed cancer experts looking to solve a different problem. A team of researchers, led by immunologist Carl June, genetically altered the T cells of three leukemia patients who had failed to respond to standard cancer therapies. Reinfusing the engineered cells back into the patients appeared to cure two of them and the other patient improved. The seminal results, published in 2011, opened up a new field, dubbed chimeric antigen receptor T cells, or CAR-T, that has produced six approved cancer therapies. While CAR-T continues to reshape cancer care, enthusiasm is growing for its move into a less-obvious area: autoimmune disease. Working with one of the CAR-T inventors in 2016, Payne’s lab c...

Comparing CAR-NK and CAR T-Cell Therapies 2023

Image
One of the most promising approaches in cellular therapies is immunotherapies using engineered T cells or natural killer (NK) cells expressing chimeric antigen receptors (CARs). Will CAR-NK cell therapies overshadow traditional CAR-T options for the treatment of some cancers? As of April 2023,  more than 1,100 studies  have been launched to investigate the potential of CAR-T cell therapy under the U.S. Clinical Trial Registry. Whereas for CAR-NK cell therapy,  more than 50 studies  have been launched. While CAR T-cell therapy is more well-known and studied, there are challenges to the manufacturing of CAR T that does not exist with CAR-NK. This may prove to be a game-changer for blood cancer patients who do not have the time to wait for a CAR T-cell donor or for their own cells to be engineered for treatment. Researchers have tried to modify natural killer (NK) cells with chimeric antigen receptors (CAR) to increase potential to bind and destroy cancer cells, known a...